Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma

Gene

Volumn 563, Issue 1, 2015, Pages 103-105

  Sneddon, Sophie ^a   Leon, Justine S ^a   Dick, Ian M ^a   Cadby, Gemma ^a,c   Olsen, Nola ^c   Brims, Fraser ^a,b,c   Allcock, Richard J N ^c   Moses, Eric K ^c   Melton, Phillip E ^c   de Klerk, Nicholas ^d   Musk, A W B ^a,b,c   Robinson, Bruce W S ^a,b   Creaney, Jenette ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

BAP1; Cancer syndrome; Mesothelioma; Mutation; Sporadic; Targeted sequencing

Indexed keywords

ASBESTOS; BRCA1 ASSOCIATED PROTEIN 1; BRCA1 PROTEIN; UNCLASSIFIED DRUG; BAP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EXOME; EXON; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; AUSTRALIA; CHEMICALLY INDUCED; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; MESOTHELIOMA; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ASBESTOS; AUSTRALIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84926420195     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.03.031     Document Type: Article

References (20)

1. Adzhubei I.A., Schmidt S., Peshkin L., Ramensky V.E., Gerasimova A., Bork P., Kondrashov A.S., Sunyaev S.R. A method and server for predicting damaging missense mutations. Nat. Methods 2010, 7(4):248-249.
2. Ascoli V., Romeo E., Carnovale Scalzo C., Cozzi I., Ancona L., Cavariani F., Balestri A., Gasperini L., Forastiere F. Familial malignant mesothelioma: a population-based study in central Italy (1980-2012). Cancer Epidemiol. 2014, 38(3):273-278.
3. Betti M., Casalone E., Ferrante D., Romanelli A., Grosso F., Guarrera S., Righi L., Vatrano S., Pelosi G., Libener R., Mirabelli D., Boldorini R., Casadio C., Papotti M., Matullo G., Magnani C., Dianzani I. Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. Gene Chromosome Cancer 2015, 54(1):51-62.
4. Cadby G., Mukherjee S., Musk A.W., Reid A., Garlepp M., Dick I., Robinson C., Hui J., Fiorito G., Guarrera S., Beilby J., Melton P.E., Moses E.K., Ugolini D., Mirabelli D., Bonassi S., Magnani C., Dianzani I., Matullo G., Robinson B., Creaney J., Palmer L.J. A genome-wide association study for malignant mesothelioma risk. Lung Cancer 2013, 83(1):1-8.
5. Carbone M., Ferris L.K., Baumann F., Napolitano A., Lum C.A., Flores E.G., Gaudino G., Powers A., Bryant-Greenwood P., Krausz T., Hyjek E., Tate R., Friedberg J., Weigel T., Pass H.I., Yang H. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J. Transl. Med. 2012, 10:179.
6. de Klerk N., Alfonso H., Olsen N., Reid A., Sleith J., Palmer L., Berry G., Musk A.B. Familial aggregation of malignant mesothelioma in former workers and residents of Wittenoom, Western Australia. Int. J. Cancer 2013, 132(6):1423-1428.
7. International HapMap, C The International HapMap Project. Nature 2003, 426(6968):789-796.
8. Jongsma J., van Montfort E., Vooijs M., Zevenhoven J., Krimpenfort P., van der Valk M., van de Vijver M., Berns A. A conditional mouse model for malignant mesothelioma. Cancer Cell 2008, 13(3):261-271.
9. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U. S. A. 1971, 68(4):820-823.
10. Kumar P., Henikoff S., Ng P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 2009, 4(7):1073-1081.
11. McKenna A., Hanna M., Banks E., Sivachenko A., Cibulskis K., Kernytsky A., Garimella K., Altshuler D., Gabriel S., Daly M., DePristo M.A. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010, 20(9):1297-1303.
12. Popova T., Hebert L., Jacquemin V., Gad S., Caux-Moncoutier V., Dubois-d'Enghien C., Richaudeau B., Renaudin X., Sellers J., Nicolas A., Sastre-Garau X., Desjardins L., Gyapay G., Raynal V., Sinilnikova O.M., Andrieu N., Manie E., de Pauw A., Gesta P., Bonadona V., Maugard C.M., Penet C., Avril M.F., Barillot E., Cabaret O., Delattre O., Richard S., Caron O., Benfodda M., Hu H.H., Soufir N., Bressac-de Paillerets B., Stoppa-Lyonnet D., Stern M.H. Germline BAP1 mutations predispose to renal cell carcinomas. Am. J. Hum. Genet. 2013, 92(6):974-980.
13. Ribeiro C., Campelos S., Moura C.S., Machado J.C., Justino A., Parente B. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation. Ann. Oncol. 2013, 24(8):2147-2150.
14. Robinson C., van Bruggen I., Segal A., Dunham M., Sherwood A., Koentgen F., Robinson B.W., Lake R.A. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res. 2006, 66(22):10786-10794.
15. Rusch A., Ziltener G., Nackaerts K., Weder W., Stahel R.A., Felley-Bosco E. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases. Lung Cancer 2015, 87(1):77-79.
16. Testa J.R., Cheung M., Pei J., Below J.E., Tan Y., Sementino E., Cox N.J., Dogan A.U., Pass H.I., Trusa S., Hesdorffer M., Nasu M., Powers A., Rivera Z., Comertpay S., Tanji M., Gaudino G., Yang H., Carbone M. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 2011, 43(10):1022-1025.
17. Thorvaldsdottir H., Robinson J.T., Mesirov J.P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 2013, 14(2):178-192.
18. Wang K., Li M., Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010, 38(16):e164.
19. Wiesner T., Obenauf A.C., Murali R., Fried I., Griewank K.G., Ulz P., Windpassinger C., Wackernagel W., Loy S., Wolf I., Viale A., Lash A.E., Pirun M., Socci N.D., Rutten A., Palmedo G., Abramson D., Offit K., Ott A., Becker J.C., Cerroni L., Kutzner H., Bastian B.C., Speicher M.R. Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 2011, 43(10):1018-1021.
20. Xu J., Kadariya Y., Cheung M., Pei J., Talarchek J., Sementino E., Tan Y., Menges C.W., Cai K.Q., Litwin S., Peng H., Karar J., Rauscher F.J., Testa J.R. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res. 2014, 74(16):4388-4397.